Skip to main content
SpringerLink
Log in

Effect of SERMs on breast tissue

  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Gallup survey findings: overview of perceived and real health threats. Gallup Survey, 1995.

  2. Cancer Facts & Figures-1998. Atlanta, American Cancer Society, 1998.

  3. 1998 Heart and Stroke Statistical Update. Dallas, American Heart Association, 1998.

  4. Feuer E.J., Wun L.-M., Boring C.C., Flanders W.D., Timmel M.J., Tong T. The lifetime risk of developing breast cancer. J. Natl. Cancer Inst. 1993, 85: 892–897.

    Article  CAS  PubMed  Google Scholar 

  5. US Bureau of the Census. Population projections of the United States by age, sex, race, and hispanic origin: 1995 to 2050. In: Current Population Reports. Washington, Government Printing Office, 1996 48, 72, 78, 80, 88. Series P25–1130.

    Google Scholar 

  6. National Center for Health Statistics. Current Estimates from the National Health Interview Survey: 1992. Hyattsville, Md: US Dept of Health and Human Services; 1994, 115. Series 10, No 189. DHSS Publications No. (PHS) 94–1517.

    Google Scholar 

  7. Hammond C.B. Women’s concerns with hormone replacement therapy compliance issues. Fertil. Steril. 1994, 62 (Suppl. 2): 157S–160S.

    CAS  PubMed  Google Scholar 

  8. Morrow M. Breast cancer: Who and Why? In: Jordan V.C. (ed.), Tamoxifen. A Guide for Clinicians and Patients. Huntington, New York., PRR, Inc. 1996, p. 1–14.

    Google Scholar 

  9. Bret K.M., Madans J.H. Use of postmenopausal hormone replacement therapy: estimates from a nationally representative cohort study. Am. J. Epidemiol. 1997, 145: 536–545.

    Article  Google Scholar 

  10. Ravnikar V.A. Compliance with hormone replacement therapy: are women receiving the full impact of hormone replacement therapy preventative health benefits? Womens Health Issues 1992, 2: 75.

    Article  CAS  PubMed  Google Scholar 

  11. Bryant H.U., Dere W.H. Selective estrogen receptor modulators: an alternative to hormone replacement therapy. Proc. Soc. Exp. Biol. Med. 1998, 217: 45–52.

    Article  CAS  PubMed  Google Scholar 

  12. Goldstein S.R., Scheele W.H., Symanowski S.M., Neale S., Shah A., Lafortune M., et al. Uterine safety considerations for selective estrogen receptor modulators. Menopause 1977, 4: 250.

    Article  Google Scholar 

  13. Goldstein S.R., Srikanth R., Parsons A.K. Effects of Raloxifene on the endometrium in healthy postmenopausal women. J. Ultrasound Med. 1999, 18: S111.

    Google Scholar 

  14. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997, 350: 1047–1059.

    Article  Google Scholar 

  15. Jordan V.C. Designer estrogens. Sci. Am. 1998, 279: 60–67.

    Article  CAS  PubMed  Google Scholar 

  16. Colditz G.A., Hankinson S.E., Hunter D.J., Willet W.C., Manson J.E., Stampfer M.J., Hennekens C., Rosner B., Speizer F.E. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N. Engl. J. Med. 1995, 332: 1589–1593.

    Article  CAS  PubMed  Google Scholar 

  17. Jaiyesimi I.A., Buzdar A.U., Decker D.A., Hortobagyi G.N. Use of tamoxifen for breast cancer: twenty-eight years later. J. Clin. Oncol. 1995, 13: 513–529.

    CAS  PubMed  Google Scholar 

  18. Early Breast Cancer Trialists’ Collaborative Group. Effects of tamoxifen and of cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomized trials among 28,896 women. N. Engl. J. Med. 1988, 319: 1681–1692.

    Article  Google Scholar 

  19. Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1998, 351: 1415–1467.

    Google Scholar 

  20. Osborne C.K. Tamoxifen in the treatment of breast cancer. N. Engl. J. Med. 1998, 339: 1609–1618.

    Article  CAS  PubMed  Google Scholar 

  21. Lippman M.E., Osborne C.K., Knazek R., Young N. In vitro model systems for the study of hormone-dependent human breast cancer. N. Engl. J. Med. 1977, 296: 154–159.

    Article  CAS  PubMed  Google Scholar 

  22. Osborne C.K., Hobbs K., Clark G. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res. 1985, 45: 584–590.

    CAS  PubMed  Google Scholar 

  23. Jordan V.C. Antitumor activity of the antiestrogen ICI 46,474 (tamoxifen) in the dimethylebezanthracene (DMBA) — induced rat mammary carcinoma mode. J. Steroid Biochem. 1974, 5: 354.

    Article  Google Scholar 

  24. Jordan V.C., Allen K.E. Evaluation of the antitumor activity of the non steroidal antiestrogen monohydroxytamoxifen in the DMBA induced rat mammary carcinoma mode. Eur. J. Cancer 1980, 16: 239–251.

    Article  CAS  PubMed  Google Scholar 

  25. Gail M.H., Brinton L.A., Byar D.P., Corle D.K., Green S.B., Schairer C., Mulvi Hill J.J. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J. Natl. Cancer Inst. 1989, 81: 1879–1886.

    Article  CAS  PubMed  Google Scholar 

  26. Fisher B., Costantino J.P., Wickerham D.L., Redmond C.K., Kavanah M., Cronin W.M., Vogel V., Robidoux A., Dimitrov N., Atkins J., Daly M., Wieand S., Tan-Chiu E., Ford L., Wolmark N. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J. Natl. Cancer. Inst. 1998, 90: 1371–1388.

    Article  CAS  PubMed  Google Scholar 

  27. Powles T., Eeles R., Ashley S., Easton D., Chang J., Dowsett M., Tudy A., Viggers J., Davey J. Interim analysis of incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial. Lancet 1998, 352: 98–101.

    Article  CAS  PubMed  Google Scholar 

  28. Veronesi U., Maisonneuve P., Costa A., Sacchini V., Maltoni C., Roberston C., Rotmensz N., Boyle P. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomized trial among hysterectomized women. Italian Prevention Study Lancet 1998, 352: 93–97.

    CAS  Google Scholar 

  29. Short L.L., Glasebrook A.L., Adrian M.D., et al. Distinct effects of selective estrogen receptor modulators on estrogen dependent and estrogen independent human breast cancer cell proliferation. J. Bone Miner. Res. 1996, 11 (Suppl. 1): S482.

    Google Scholar 

  30. Sato M., Glasebrook A., Bryant H.U. Raloxifene: a selective estrogen receptor modulator. J. Bone Miner. Metab. 1994, 12 (Suppl. 2): S9–S20.

    Article  CAS  Google Scholar 

  31. Hol T., Cox M.B., Bryant H.U., Draper M.W. Selective estrogen receptor modulators and postmenopausal women’s health. J. Womens Health 1997, 6: 523–531.

    Article  CAS  PubMed  Google Scholar 

  32. Buzdar A.U., Marcus C., Holmes F., Hug V., Hortobagyi G. Phase II evaluation of LY156758 in metastatic breast cancer. Oncology 1988, 45: 344–345.

    Article  CAS  PubMed  Google Scholar 

  33. Killackey M., Hakes T., Pierce V. Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat. Rep. 1985, 69: 237–238.

    CAS  PubMed  Google Scholar 

  34. Jordan V.C. Tamoxifen and endometrial cancer [Letter]. Lancet 1989, 2: 117–20.

    Google Scholar 

  35. Neven P., Muylder X., Van Belle Y., Vanderick G., De Mylder E. Hysteroscopic follow-up during tamoxifen treatment. Eur. J. Obstet. Gynecol. Reprod. Biol. 1990, 35: 235–238.

    Article  CAS  PubMed  Google Scholar 

  36. Delmas P.D., Bjarnason N.H., Mitlak B.H., Ravoux A.C., Shah A.S., Huster W.J., Draper M., Christiansen C. The effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N. Engl. J. Med. 1997, 337: 1641–7.

    Article  CAS  PubMed  Google Scholar 

  37. Jordan V.C., Glusman J.E., Eckert S., et al. Raloxifene reduces incident primary breast cancers: integrated data from multicenter, double blind, randomized trials in postmenopausal women. Abstract presented at the 21st Annual San Antonio Breast Cancer Symposium. San Antonio, December 12–15, 1998.

    Google Scholar 

  38. Cummings S.R., Norton L., Eckert S., et al. Raloxifene reduces the risk of breast cancer and may decrease the risk of endometrial cancer in postmenopausal women: two-year findings from the multiple outcomes of raloxifene evaluation (MORE) trial. Proc. Am. Soc. Clin. Oncol. 1998, 17. Abstract 3.

Download references

Author information

Authors and Affiliations

  1. New York University Medical Center, 530 First Avenue, Suite 10N, New York, NY, 10016, USA

    Steven R. Goldstein M.D. (Professor OB/GYN)

Authors
  1. Steven R. Goldstein M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Goldstein, S.R. Effect of SERMs on breast tissue. J Endocrinol Invest 22, 636–640 (1999). https://doi.org/10.1007/BF03343621

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03343621

Key-words

Search

Navigation